Amvuttra® (vutrisiran) – New indication
March 20, 2025 - Alnylam announced the FDA approval of Amvuttra (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
Top